Eder

2006-2009 Doctoral thesis, University of Heidelberg and German Cancer Research Center Heidelberg
2009-2012 German Cancer Research Center, Heidelberg, postdoc
2013-2015 Group leader “Radiopharmaceutical Sciences” in the Division Radiopharmaceutical Chemistry, German Cancer Research Center Heidelberg
2015-2017 Research Group in the Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center Heidelberg and University Hospital, Heidelberg
Since 2017 Full Professor (W3) of Radiopharmaceutical Development, Medical Center – University of Freiburg/ DKTK

Translational radiopharmaceutical sciences
Development of novel radiopharmaceuticals for the diagnosis and therapy in Nuclear Medicine
Theranostics

Kratochwil C, ... Eder M, Kopka K, Haberkorn U. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57:1170-6.
Benesova M, ... Eder M. Linker Modification Strategies to Control the Prostate-Specifc Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTAConjugated PSMA Inhibitors. Journal of Medicinal Chemistry. 2016; 59:1761-75.
Benesova M, ... Eder M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine 2015; 56:914-20.
Afshar-Oromieh A, ... Eder M, ... Haberkorn U. The diagnostic value of PET/CT imaging with the Galabelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42:197-209.
Eder et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97.

Biotechnological methods for the development of novel radiopharmaceuticals in nuclear medicine